Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Roivant SciencesROIVW -3.85%51 3-1 Month Momentum % is N/A% as of Jul. 25, 2026. GuruFocus rates ROIVW with a GF Score™ of 51/100. The stock has 7 warning signs investors should review. Among 1,392 Biotechnology companies, Roivant Sciences ranks better than 83.33% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-25), Roivant Sciences's 3-1 Month Momentum % is N/A%.
The industry rank for Roivant Sciences's 3-1 Month Momentum % or its related term are showing as below:
ROIVW's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -10.615 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Roivant Sciences 3-1 Month Momentum % Related Terms
ROIVW vs RPRX, BNTX, INCY: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Roivant Sciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roivant Sciences 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Roivant Sciences's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Roivant Sciences's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roivant Sciences (ROIVW) has a 3-1 Month Momentum % of N/A% as of Jul. 25, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Roivant Sciences and its competitors. According to the industry distribution chart, Roivant Sciences ranks #232 out of 1392 companies in the Biotechnology industry, placing it in the top 16.7%.
Is Roivant Sciences' 3-1 Month Momentum % too high?
Roivant Sciences' current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Roivant Sciences ranks #232 out of 1392 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Roivant Sciences has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' 3-1 Month Momentum % compare to RPRX and BNTX?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #232 out of 1392 companies for 3-1 Month Momentum %. This places Roivant Sciences in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Roivant Sciences and its competitors. Roivant Sciences's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Roivant Sciences (ROIVW) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. Roivant Sciences' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Roivant Sciences (ROIVW), the current 3-1 Month Momentum % is N/A% as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
51GF Score
Get the complete analysis for ROIVW
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROIVW has been successfully added to your 
